A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

437

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

October 15, 2027

Study Completion Date

October 15, 2027

Conditions
Advanced Malignant Tumors
Interventions
DRUG

BMS-986488

Specified dose on specified days

DRUG

Adagrasib

Specified dose on specified days

DRUG

Cetuximab

Specified dose on specified days

DRUG

Nivolumab

Specified dose on specified days

Trial Locations (8)

4029

NOT_YET_RECRUITING

Local Institution - 0031, Brisbane

18103

RECRUITING

Lehigh Valley Health Network, Allentown

38138

RECRUITING

The West Clinic, PLLC dba West Cancer Center, Germantown

75390

NOT_YET_RECRUITING

Local Institution - 0025, Dallas

07601

RECRUITING

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

V5Z 4E6

RECRUITING

BC Cancer Vancouver, Vancouver

H2X 0A9

NOT_YET_RECRUITING

Local Institution - 0015, Montreal

G1J 1Z4

RECRUITING

Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus, Québec

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06764771 - A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors | Biotech Hunter | Biotech Hunter